SEC Form S-8 filed by Fate Therapeutics Inc.
As filed with the Securities and Exchange Commission on June 10, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
FATE THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 65-1311552 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
12278 Scripps Summit Drive San Diego, CA |
92131 | |
(Address of Principal Executive Offices) | (Zip Code) |
FATE THERAPEUTICS, INC. AMENDED AND RESTATED 2022 STOCK OPTION AND INCENTIVE PLAN
(Full title of the plan)
J. Scott Wolchko
President and Chief Executive Officer
Fate Therapeutics, Inc.
12278 Scripps Summit Drive
San Diego, CA 92131
(Name and address of agent for service)
(858) 875-1800
(Telephone number, including area code, of agent for service)
Copies to:
Kingsley L. Taft, Esq. Maggie L. Wong, Esq. Natalie T. Martirossian, Esq. Goodwin Procter LLP 3 Embarcadero Center, 28th Floor San Francisco, CA 94111 Telephone: (415) 733-6000 |
Cindy R. Tahl, Esq. General Counsel and Corporate Secretary Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego, CA 92131 Telephone: (858) 875-1800 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE
On April 1, 2024, the Board of Directors of Fate Therapeutics, Inc. (the “Company”) adopted, subject to approval by stockholders, the Fate Therapeutics, Inc. Amended and Restated 2022 Stock Option and Incentive Plan (the “A&R 2022 Plan”), which the stockholders of the Company approved at the Company’s 2024 Annual Meeting of Stockholders held on June 7, 2024. The A&R 2022 Plan increased the number of shares of common stock, par value $0.001 per share, of the Company (“Common Stock”) authorized for issuance thereunder by 8,000,000 shares to a new total of 17,500,000 shares of Common Stock. The A&R 2022 Plan will otherwise continue in effect through its current term (June 2032), unless terminated earlier by the Company’s Board of Directors.
The Company is filing this registration statement on Form S-8 (this “Registration Statement”) solely for the purpose of registering the 8,000,000 additional shares of Common Stock authorized for issuance under the A&R 2022 Plan. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also includes an indeterminate number of additional shares of Common Stock that may become issuable under the A&R 2022 Plan by reason of anti-dilution and other adjustments.
REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E
Pursuant to General Instruction E of Form S-8, the Company is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register an additional 8,000,000 shares of its Common Stock under the A&R 2022 Plan. Such additional shares are of the same class as other securities for which a registration statement relating to the A&R 2022 Plan has previously been filed and is effective. Pursuant to General Instruction E of Form S-8 regarding Registration of Additional Securities, the contents of the Company’s Registration Statement on Form S-8 (File No. 333-265502), filed with the Commission on June 9, 2022, is hereby incorporated by reference.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on this 10th day of June, 2024.
FATE THERAPEUTICS, INC. | ||
By: | /s/ J. Scott Wolchko | |
J. Scott Wolchko | ||
President and Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby severally constitutes and appoints each of J. Scott Wolchko, Edward J. Dulac III and Cindy R. Tahl, and each of them singly, as such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in such person’s name, place and stead, in any and all capacities, to sign any or all amendments (including, without limitation, post-effective amendments) to this registration statement (or any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
/s/ J. Scott Wolchko |
President, Chief Executive Officer and Director | June 10, 2024 | ||
J. Scott Wolchko | (Principal Executive Officer) | |||
/s/ Edward Dulac |
Chief Financial Officer | June 10, 2024 | ||
Edward Dulac | (Principal Financial and Accounting Officer) | |||
/s/ William H. Rastetter |
Chairman of the Board and Director | June 10, 2024 | ||
William H. Rastetter, Ph.D. | ||||
/s/ John D. Mendlein |
Vice Chairman of the Board and Director | June 10, 2024 | ||
John D. Mendlein, Ph.D., J.D. | ||||
/s/ Timothy P. Coughlin |
Director | June 10, 2024 | ||
Timothy P. Coughlin | ||||
/s/ Michael Lee |
Director | June 10, 2024 | ||
Michael Lee | ||||
/s/ Robert S. Epstein |
Director | June 10, 2024 | ||
Robert S. Epstein, M.D., M.S. | ||||
/s/ Karin Jooss |
Director | June 10, 2024 | ||
Karin Jooss, Ph.D. | ||||
/s/ Shefali Agarwal |
Director | June 10, 2024 | ||
Shefali Agarwal, M.D. | ||||
/s/ Yuan Xu |
Director | June 10, 2024 | ||
Yuan Xu, Ph. D. |